Prof. Dr. Peter Falkai

Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich

Prof. Dr. Peter Falkai

Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich


Professional Career

01.7.2012 to present                       Professor and Chairman; Department of Psychiatry and Psychotherapy Ludwig-Maximilians-University Munich

01.08.2006- 30.6.2012                    Professor and Chairman; Department of Psychiatry and Psychotherapy University of Göttingen, Germany

01.08.2002 – 31.07.2006                 Professor and Chairman; Department of Psychiatry and Psychotherapy University of Saarland, Homburg/Saar (Germany)


  1. Kurt-Schneider-Preis 2015; Award supported with 10.000€
  2. Kraepelin-Award 2004, with a support of 7.500€
  3. Various Stanley Award Centre Grants

Scientific Societies – Memberships

2011 to 2012 Chairman of the Deutsche Gesellschaft für Psychiatrie und Psychotherapie (DGPPN) (Board member since 1995); Member of: The National Academy of Sciences Leopoldina; German Research Foundation (DFG); The German Society of Neurogenetics (DGNG); Europäische Arbeitsgemeinschaft Gerontopsychiatrie (EAG); Arbeitsgemeinschaft für Neuropsychopharmakologie (AGNP); Neurowissenschaftliche Gesellschaft (NWG);  Schizophrenia International Research Society (SIRS)

Scientific Activities

2007 to 2010 Chairman of the Deutsche Gesellschaft für Biologische Psychiatrie (DGBP); Since 2013 Chairman of the Council of National Societies (NPAs) of the European Psychiatric Association (EPA); Membership in Editorial/Advisory Boards (i.e. Chief-Editor – European Archives of Psychiatry and Clinical Neuroscience, Springer); Reviewer for scientific journals (i.e. Biol Psychiatry, JAMA Psychiatry, Mol Psychiatry, Am J Psychiatry, Schizophr Bull, Schizophr Res, Transl Psychiat, World J Biol Psychiatry, Lancet); Expert for funding institutions with peer-review procedure: Total Research Support funding since 1994: 11.698.207 EUR

Current Funding: DFG: (PI) Speaker Clinical Research Group 241 (KFO 241). 01/2012 to 12/2016; DFG: (Co-PI) Prolongation of KFO 241: PsyCourse – Genotype-Phenotype relationships and neurobiology of the longitudinal course of psychosis (FA241/16-1). 01/2015-12/2017; EU: Marie-Curie (PI) Deciphering Inter- and Intracellular Signalling in Schizophrenia IN-SENS ( FP7-PEOPLE-2013 (607616); 12/2013-11/2016

BMBF: (PI) ESPRIT: Enhancing schizophrenia prevention and recovery by innovative treatments; Aerobic exercise, tDCS, N-acetylcysteine and cannabidiol treatment in schizophrenia (01EE1407E). 09/2014-08/2018; BMBF: (PI) e: Med Integrament (01ZX1314I): Epigenetics and transcriptome plasticity in psychiatric diseases. 01/2014-12/2017; BMBF: (PI) COMBINE: Combined treatment of olanzapine and amilsupride in schizophrenia (EudraCT: 2011-002463-20). 09/2013-12/2015; Max-Planck-Society: (Co-PI) International Max Planck Research School on Translational Psychiatry (IMPRS-TP). 01/2016-12/2021; Robert-Vogel-Stiftung: Frühprädiktion und Frührehabilitation von jungen Menschen mit schizophrenen und affektiven Erkrankungen (CHANCE). 2016-2021; Leopoldina: (PI) Arbeit und psychische Erkrankungen- eine gesellschaftliche Herausforderung. 07/2015-11/2016;

Stanley Foundation: (PI) Add-on spironolactone for the treatment of schizophrenia (SPIRO-TREAT), EUDRACT: 2014-001968-35 (Stanley Foundation). 11/2014-10/2017 .


  • Hirsch-Index: 57 (Web of Science/ThomsonReuter). Total Pub Med indexed number of publications as of 10.01.2016: 463
  • Creator of treatment guidelines for schizophrenia for the WFSBP; Creator of S3 treatment guidelines for the DGPPN